Education
About Us
Working with TipRanks
Follow Us
Mabion SA (PL:MAB)
:MAB
MAB Stock Chart & Stats
Day’s Range― - ―
52-Week Rangezł8.00 - zł16.56
Previous CloseN/A
VolumeN/A
Average Volume (3M)40.13K
Market Cap
€143.04M
Enterprise Valuezł152.41M
Total Cash (Recent Filing)€23.69M
Total Debt (Recent Filing)€3.56M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding16,162,327
10 Day Avg. Volume42,872
30 Day Avg. Volume40,129
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.29
Price to Sales (P/S)2.08
P/FCF Ratio5.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.51Price Target Upside-3.87% Downside
Rating ConsensusHold
Number of Analyst Covering1
MAB FAQ
What was Mabion SA’s price range in the past 12 months?
Mabion SA lowest stock price was zł8.00 and its highest was zł16.56 in the past 12 months.
What is Mabion SA’s market cap?
Mabion SA’s market cap is €143.04M.
When is Mabion SA’s upcoming earnings report date?
Mabion SA’s upcoming earnings report date is Nov 04, 2025 which is in 29 days.
How were Mabion SA’s earnings last quarter?
Mabion SA released its earnings results on Sep 09, 2025. The company reported -zł0.954 earnings per share for the quarter, missing the consensus estimate of N/A by -zł0.954.
Is Mabion SA overvalued?
According to Wall Street analysts Mabion SA’s price is currently Overvalued.
Does Mabion SA pay dividends?
Mabion SA does not currently pay dividends.
What is Mabion SA’s EPS estimate?
Mabion SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabion SA have?
Mabion SA has 16,162,327 shares outstanding.
What happened to Mabion SA’s price movement after its last earnings report?
Mabion SA reported an EPS of -zł0.954 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.939%.
Which hedge fund is a major shareholder of Mabion SA?
Currently, no hedge funds are holding shares in PL:MAB
Company Description
Mabion SA
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Technical Analysis
Ryvu Therapeutics SA
―
Scope Fluidics SA
―
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―